DANBURY, Conn. - MannKind (NASDAQ:MNKD) Corporation (NASDAQ:MNKD), a biopharmaceutical company currently valued at $1.64 billion and showing strong financial health according to InvestingPro metrics, has reached agreements to significantly reduce its outstanding debt through a series of transactions involving its convertible notes. The company, which has achieved impressive revenue growth of 51.35% over the last twelve months, announced on Monday that it entered into privately negotiated exchange agreements with certain holders of its 2.50% Convertible Senior Notes due 2026.
Under the agreement, the holders will exchange approximately $193.7 million of the notes for roughly 26.7 million shares of MannKind’s common stock. Additionally, MannKind will pay the holders about $89.2 million in cash as extra exchange consideration. These transactions are set to occur in two phases, with the first closing expected around December 20, 2024, and the second around December 23, 2024, pending standard closing conditions.
This exchange will cut MannKind's total outstanding debt by 84%, reducing the principal amount of the notes from $230 million to approximately $36.3 million. The company’s annual interest expense will also decrease by $4.9 million to about $0.9 million. By reducing the number of shares reserved for the conversion of the notes, MannKind anticipates a savings of around 10.4 million shares of potential dilution.
Post-exchange, MannKind’s cash reserves are expected to exceed $180 million, with approximately 302.5 million shares outstanding. This move is aimed at enhancing the company's financial flexibility to support growth and development of its pulmonary pipeline programs.
The shares issued in this exchange have not been registered under the Securities Act of 1933 and may not be sold in the United States absent registration or an exemption from registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities.
MannKind focuses on the development and commercialization of inhaled therapeutic products for diseases such as diabetes and pulmonary conditions. The company’s proprietary technologies allow for rapid delivery of medication to the lungs.
The information in this article is based on a press release statement from MannKind Corporation.
In other recent news, MannKind Corporation has announced significant financial and operational developments. The biopharmaceutical company reported a robust financial performance in Q3 2024, with revenues increasing by 37% to reach $70 million. This growth was significantly contributed by the Tyvaso DPI collaboration and Afrezza prescriptions, which generated $20 million and $15 million in net revenue, respectively.
MannKind also revealed agreements to exchange approximately $193.7 million of its convertible senior notes for shares and cash. As part of the exchange, note holders will receive an aggregate of 26,749,559 shares of MannKind's common stock and a total cash payment of about $89.2 million.
Furthermore, the company is making progress with its clinical pipeline, with Clofazamine in Phase 3 and nintedanib completing Phase 1 trials. Looking ahead, MannKind plans to shift its focus to growth in 2025, particularly in the pediatric diabetes market through its product Afrezza.
However, the company has experienced a slight decline in overall rapid-acting insulin prescriptions and a reduction in non-target prescriptions due to a strategic reduction in the salesforce. Despite these challenges, regulatory updates for Afrezza with a potential pre-NDA filing meeting are anticipated in the first half of 2025. These are the most recent developments for MannKind Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.